Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs
Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.
Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously. This story matters for Finance & Markets readers tracking fund. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. FundNews curates and briefs the finance & markets stories that matter. Our editorial policy →